Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 25Pituitary Neoplasms 10Pheochromocytoma 10Carcinoma, Neuroendocrine 9Thyroid Neoplasms 8Sarcoma 8Thyroid Cancer, Papillary 6Paraganglioma 5Ovarian Neoplasms 5Neuroblastoma 5Adrenocortical Carcinoma 5Small Cell Lung Carcinoma 4Parathyroid Neoplasms 4Pancreatic Neoplasms 4Osteosarcoma 4Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Medullary 4Adrenal Gland Neoplasms 4Thyroid Carcinoma, Anaplastic 3Stomach Neoplasms 3Prostatic Neoplasms 3Pituitary ACTH Hypersecretion 3Melanoma 3Head and Neck Neoplasms 3Cushing Syndrome 3Colorectal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Hepatocellular 3

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Digestive System Neuroendocrine Tumor G1 × Endocrine × 30 days × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡